The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization
BackgroundTransarterial chemoembolization(TACE) is the suggested treatment for hepatocellular carcinoma (HCC) not amenable to curative treatments. We investigated the role of sarcopenia on overall survival in HCC patients receiving TACE and proposed a new prognostic scoring system incorporating sarc...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1005571/full |
| _version_ | 1811265524517044224 |
|---|---|
| author | Tzu-Ping Chien Song-Fong Huang Song-Fong Huang Wen-Hui Chan Wen-Hui Chan Kuang-Tse Pan Kuang-Tse Pan Ming-Chin Yu Ming-Chin Yu Ming-Chin Yu Wei-Chen Lee Wei-Chen Lee Hsin-I Tsai Hsin-I Tsai Hsin-I Tsai Po-Ting Lin Po-Ting Lin Hsing-Yu Chen Hsing-Yu Chen Hsing-Yu Chen Jui-Hsuan Chen Jui-Hsuan Chen Chao-Wei Lee Chao-Wei Lee Chao-Wei Lee |
| author_facet | Tzu-Ping Chien Song-Fong Huang Song-Fong Huang Wen-Hui Chan Wen-Hui Chan Kuang-Tse Pan Kuang-Tse Pan Ming-Chin Yu Ming-Chin Yu Ming-Chin Yu Wei-Chen Lee Wei-Chen Lee Hsin-I Tsai Hsin-I Tsai Hsin-I Tsai Po-Ting Lin Po-Ting Lin Hsing-Yu Chen Hsing-Yu Chen Hsing-Yu Chen Jui-Hsuan Chen Jui-Hsuan Chen Chao-Wei Lee Chao-Wei Lee Chao-Wei Lee |
| author_sort | Tzu-Ping Chien |
| collection | DOAJ |
| description | BackgroundTransarterial chemoembolization(TACE) is the suggested treatment for hepatocellular carcinoma (HCC) not amenable to curative treatments. We investigated the role of sarcopenia on overall survival in HCC patients receiving TACE and proposed a new prognostic scoring system incorporating sarcopenia.Materials and methodsWe retrospectively analyzed 260 HCC patients who received TACE between 2010 and 2015. Total psoas muscle was measured on a cross-sectional CT image before the first TACE session. Sarcopenia was defined by the pre-determined sex-specific cutoff value. We assessed the impact of sarcopenia and other biochemical factors on the overall survival and compared the new scoring system with other prognostic scoring systems.ResultsOne hundred and thirty patients (50%) were classified as sarcopenia before the first TACE. They were older with a higher male tendency and a significantly lower body mass index (BMI). Cox regression multivariate analysis demonstrated that sarcopenia, multiple tumors, maximal tumor diameter≥ 5cm, major venous thrombosis, sarcopenia, AFP ≥ 200 ng/ml, and albumin<3.5mg/dL were independent poor prognostic factors for overall survival in HCC patients receiving TACE. Our scoring system comprising these factors outperformed other major scoring systems in terms of predicting survival after TACE.ConclusionThe current study demonstrated that sarcopenia was an independent prognostic factor for HCC undergoing TACE therapy. Our newly developed scoring system could effectively predict patient survival after TACE. Physicians could, based on the current score model, carefully select candidate patients for TACE treatment in order to optimize their survival. Further studies are warranted to validate our findings. |
| first_indexed | 2024-04-12T20:25:21Z |
| format | Article |
| id | doaj.art-a6a54043073d40c49db9aa61a7bb8a40 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T20:25:21Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-a6a54043073d40c49db9aa61a7bb8a402022-12-22T03:17:53ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-09-011210.3389/fonc.2022.10055711005571The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolizationTzu-Ping Chien0Song-Fong Huang1Song-Fong Huang2Wen-Hui Chan3Wen-Hui Chan4Kuang-Tse Pan5Kuang-Tse Pan6Ming-Chin Yu7Ming-Chin Yu8Ming-Chin Yu9Wei-Chen Lee10Wei-Chen Lee11Hsin-I Tsai12Hsin-I Tsai13Hsin-I Tsai14Po-Ting Lin15Po-Ting Lin16Hsing-Yu Chen17Hsing-Yu Chen18Hsing-Yu Chen19Jui-Hsuan Chen20Jui-Hsuan Chen21Chao-Wei Lee22Chao-Wei Lee23Chao-Wei Lee24Division of General Surgery, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, TaiwanDivision of General Surgery, Department of Surgery, New Taipei Municipal Tu-Cheng Hospital (Built and Operated by Chang Gung Medical Foundation), New Taipei City, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanDepartment of Medical Imaging and Intervention, Linkou Chang Gung Memorial Hospital, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanDepartment of Medical Imaging and Intervention, Linkou Chang Gung Memorial Hospital, Taoyuan, TaiwanDivision of General Surgery, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, TaiwanDivision of General Surgery, Department of Surgery, New Taipei Municipal Tu-Cheng Hospital (Built and Operated by Chang Gung Medical Foundation), New Taipei City, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanDivision of General Surgery, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanDepartment of Anesthesiology, Linkou Chang Gung Memorial Hospital, Taoyuan, TaiwanGraduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanDepartment of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan, TaiwanGraduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, TaiwanDivision of Chinese Internal Medicine, Center for Traditional Chinese Medicine, Taoyuan Chang Gung Memorial Hospital, Taoyuan, TaiwanSchool of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, Taiwan0Department of Nursing, Linkou Chang Gung Memorial Hospital, Taoyuan, TaiwanDivision of General Surgery, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanGraduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, TaiwanBackgroundTransarterial chemoembolization(TACE) is the suggested treatment for hepatocellular carcinoma (HCC) not amenable to curative treatments. We investigated the role of sarcopenia on overall survival in HCC patients receiving TACE and proposed a new prognostic scoring system incorporating sarcopenia.Materials and methodsWe retrospectively analyzed 260 HCC patients who received TACE between 2010 and 2015. Total psoas muscle was measured on a cross-sectional CT image before the first TACE session. Sarcopenia was defined by the pre-determined sex-specific cutoff value. We assessed the impact of sarcopenia and other biochemical factors on the overall survival and compared the new scoring system with other prognostic scoring systems.ResultsOne hundred and thirty patients (50%) were classified as sarcopenia before the first TACE. They were older with a higher male tendency and a significantly lower body mass index (BMI). Cox regression multivariate analysis demonstrated that sarcopenia, multiple tumors, maximal tumor diameter≥ 5cm, major venous thrombosis, sarcopenia, AFP ≥ 200 ng/ml, and albumin<3.5mg/dL were independent poor prognostic factors for overall survival in HCC patients receiving TACE. Our scoring system comprising these factors outperformed other major scoring systems in terms of predicting survival after TACE.ConclusionThe current study demonstrated that sarcopenia was an independent prognostic factor for HCC undergoing TACE therapy. Our newly developed scoring system could effectively predict patient survival after TACE. Physicians could, based on the current score model, carefully select candidate patients for TACE treatment in order to optimize their survival. Further studies are warranted to validate our findings.https://www.frontiersin.org/articles/10.3389/fonc.2022.1005571/fullhepatocellular carcinomasarcopeniatransarterial chemoembolization (TACE)survival (MeSH)biochemical factors |
| spellingShingle | Tzu-Ping Chien Song-Fong Huang Song-Fong Huang Wen-Hui Chan Wen-Hui Chan Kuang-Tse Pan Kuang-Tse Pan Ming-Chin Yu Ming-Chin Yu Ming-Chin Yu Wei-Chen Lee Wei-Chen Lee Hsin-I Tsai Hsin-I Tsai Hsin-I Tsai Po-Ting Lin Po-Ting Lin Hsing-Yu Chen Hsing-Yu Chen Hsing-Yu Chen Jui-Hsuan Chen Jui-Hsuan Chen Chao-Wei Lee Chao-Wei Lee Chao-Wei Lee The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization Frontiers in Oncology hepatocellular carcinoma sarcopenia transarterial chemoembolization (TACE) survival (MeSH) biochemical factors |
| title | The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization |
| title_full | The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization |
| title_fullStr | The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization |
| title_full_unstemmed | The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization |
| title_short | The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization |
| title_sort | combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization |
| topic | hepatocellular carcinoma sarcopenia transarterial chemoembolization (TACE) survival (MeSH) biochemical factors |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.1005571/full |
| work_keys_str_mv | AT tzupingchien thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT songfonghuang thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT songfonghuang thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT wenhuichan thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT wenhuichan thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT kuangtsepan thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT kuangtsepan thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT mingchinyu thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT mingchinyu thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT mingchinyu thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT weichenlee thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT weichenlee thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT hsinitsai thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT hsinitsai thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT hsinitsai thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT potinglin thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT potinglin thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT hsingyuchen thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT hsingyuchen thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT hsingyuchen thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT juihsuanchen thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT juihsuanchen thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT chaoweilee thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT chaoweilee thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT chaoweilee thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT tzupingchien combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT songfonghuang combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT songfonghuang combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT wenhuichan combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT wenhuichan combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT kuangtsepan combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT kuangtsepan combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT mingchinyu combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT mingchinyu combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT mingchinyu combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT weichenlee combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT weichenlee combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT hsinitsai combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT hsinitsai combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT hsinitsai combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT potinglin combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT potinglin combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT hsingyuchen combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT hsingyuchen combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT hsingyuchen combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT juihsuanchen combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT juihsuanchen combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT chaoweilee combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT chaoweilee combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT chaoweilee combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization |